Explosion in Psoriasis Drug Development Promising

LAS VEGAS – There are so many psoriasis medications that have been approved or are in the experimental pipeline that it can be hard to track them all.

"I can't even keep them straight," Dr. Craig L. Leonardi said. "It's an amazing time right now."

He mapped out the major trends in psoriasis medications for physicians at a dermatology seminar sponsored by Skin Disease Education Foundation (SDEF).

The armamentarium started off with T-cell inhibitors, the main one being alefacept, said Dr. Leonardi of St. Louis University. "I'm not aware of any other T-cell inhibitors that are in development right now. This seems to be a strategy that has been pushed off to the side for now."

On the other hand, psoriasis drugs involving cytokines and cytokine inhibitors are booming. A few other anti-inflammatory strategies also are being tested, including activation of the sirtuin 1 (SIRT1) protein, an oral phospholipid analog, an oral phosphodiesterase inhibitor, and a drug that inhibits Janus kinase (JAK) 1 and 3.

Cytokines: "Cytokines and cytokine inhibitors are exploding," Dr. Leonardi said. The five approved tumor necrosis factor (TNF) antagonists – adalimumab, certolizumab, etanercept, infliximab, and golimumab – "have great utility," he said.

There are two drugs that block both interleukins (IL) 12 and 23. Ustekinumab is approved, and Abbott Laboratories in January 2011 withdrew its biologics license application for briakinumab to perform additional studies at the request of regulators. These two drugs seem to have a "class effect" associated with increased risk of major cardiovascular events, Dr. Leonardi said.

Two other experimental drugs inhibit just IL-23. "These drugs are not interacting with IL-12 at all. If the cardiovascular signal we have seen with briakinumab and with ustekinumab is real, maybe it has to do with IL-12 more than IL-23. Maybe we'll see an improved safety profile for targeting just IL-23," he said.

Trials are underway of three drugs that inhibit IL-17 and one that targets the IL-17 receptor.

"The IL-23 drugs, IL-17 drugs, and IL-17 receptor blocker drug have a lot of briakinumab/ustekinumab feel in terms of efficacy," Dr. Leonardi said. The studies are blinded, so he doesn't know which patients are getting drug or placebo, but he's noticed that in some patients "amazing things are happening to skin and they're happening fast. This is going to be a great moment for many psoriasis sufferers" if these drugs fulfill the promises he thinks he's glimpsed.

Another trial is studying an IL-22 blocking agent.

In other categories, the novel agents being studied are oral medications, "That's a good thing for those that like that approach, but when you use oral medication, you lose a lot of the specificity that we've come to really expect with our biologic agents," he said.

Resveratrol: This compound is believed to activate SIRT1, which may have anti-inflammatory properties. Preliminary trials are underway.

VB-201: The first drug in its class, VB-201 by Vascular Biogenics is an oral phospholipid analog that downregulates production of proinflammatory cytokines by mature dendritic cells. It inhibits the shared p40 subunit of IL-12 and IL-23, and is in preliminary trials for psoriasis.

Apremilast: An oral inhibitor of type 4 phosphodiesterase (PDE4), apremilast inhibits production of inflammatory cytokines. Its mechanism of action on psoriasis is unclear. "Is it a floor wax or is it a milk shake? I can't decide. How does this drug work?" Dr. Leonardi asked.

Reports from a phase II trial by Celgene, which is developing the drug, suggest that it has multiple effects including reducing TNF-alpha, IL-2, interferon-gamma, and several leukotrienes, he said. In the trial of 260 patients, 24% of patients on a 20-mg b.i.d. dosage achieved a 75% improvement in their Psoriasis Area and Severity Index (PASI 75) score at 12 weeks, compared with 10% of patients on either a 20-mg/day dosage or placebo.

Tasocitinib: Also known as CP-690,550, this is a relatively selective inhibitor of JAK1 and JAK3. In early trials for rheumatoid arthritis, the oral drug appears to decrease inflammatory cytokines and chemokines, and decrease the influx of inflammatory cells, "so that provides a rationale for using it in psoriasis," Dr. Leonardi said.

In a phase II trial, 67% of patients on 15 mg b.i.d. achieved a PASI 75 score at 12 weeks, compared with 41% on 5 mg b.i.d., 25% on 2 mg b.i.d., and 2% on placebo. There were signals of potential safety issues with the drug, however, with a total of five major adverse events, some decreases in hemoglobin levels, transient decreases in polymorphonuclear leukocytes, and dose-related increases in lipids.

"Whether or not these are going to be significant, we'll have to wait and see," Dr. Leonardi said. "At least it showed some promise."

SDEF and this news organization are owned by Elsevier.

Dr. Leonardi declared having potential conflicts of interest with Pfizer (which is developing tasocitinib), Celgene (apremilast), Abbott (briakinumab and adalimumab), Centocor (ustekinumab, infliximab, and golimumab), Amgen (etanercept), Abgenix, Allergan, Alza, Biogen-IDEC, Boehringer-Ingelheim, Bristol-Myers Squibb, Connetics, Corixa, Fujisawa, Galderma, Genentech, Genzyme, GSK, Incyte, Isis, Lilly, MedImmune, Miravant, Schering Plough, Serono, Synta, Wyeth, and Xoma.

LAS VEGAS – There are so many psoriasis medications that have been approved or are in the experimental pipeline that it can be hard to track them all.

"I can't even keep them straight," Dr. Craig L. Leonardi said. "It's an amazing time right now."

He mapped out the major trends in psoriasis medications for physicians at a dermatology seminar sponsored by Skin Disease Education Foundation (SDEF).

The armamentarium started off with T-cell inhibitors, the main one being alefacept, said Dr. Leonardi of St. Louis University. "I'm not aware of any other T-cell inhibitors that are in development right now. This seems to be a strategy that has been pushed off to the side for now."

On the other hand, psoriasis drugs involving cytokines and cytokine inhibitors are booming. A few other anti-inflammatory strategies also are being tested, including activation of the sirtuin 1 (SIRT1) protein, an oral phospholipid analog, an oral phosphodiesterase inhibitor, and a drug that inhibits Janus kinase (JAK) 1 and 3.

Cytokines: "Cytokines and cytokine inhibitors are exploding," Dr. Leonardi said. The five approved tumor necrosis factor (TNF) antagonists – adalimumab, certolizumab, etanercept, infliximab, and golimumab – "have great utility," he said.

There are two drugs that block both interleukins (IL) 12 and 23. Ustekinumab is approved, and Abbott Laboratories in January 2011 withdrew its biologics license application for briakinumab to perform additional studies at the request of regulators. These two drugs seem to have a "class effect" associated with increased risk of major cardiovascular events, Dr. Leonardi said.

Two other experimental drugs inhibit just IL-23. "These drugs are not interacting with IL-12 at all. If the cardiovascular signal we have seen with briakinumab and with ustekinumab is real, maybe it has to do with IL-12 more than IL-23. Maybe we'll see an improved safety profile for targeting just IL-23," he said.

Trials are underway of three drugs that inhibit IL-17 and one that targets the IL-17 receptor.

"The IL-23 drugs, IL-17 drugs, and IL-17 receptor blocker drug have a lot of briakinumab/ustekinumab feel in terms of efficacy," Dr. Leonardi said. The studies are blinded, so he doesn't know which patients are getting drug or placebo, but he's noticed that in some patients "amazing things are happening to skin and they're happening fast. This is going to be a great moment for many psoriasis sufferers" if these drugs fulfill the promises he thinks he's glimpsed.

Another trial is studying an IL-22 blocking agent.

In other categories, the novel agents being studied are oral medications, "That's a good thing for those that like that approach, but when you use oral medication, you lose a lot of the specificity that we've come to really expect with our biologic agents," he said.

Resveratrol: This compound is believed to activate SIRT1, which may have anti-inflammatory properties. Preliminary trials are underway.

VB-201: The first drug in its class, VB-201 by Vascular Biogenics is an oral phospholipid analog that downregulates production of proinflammatory cytokines by mature dendritic cells. It inhibits the shared p40 subunit of IL-12 and IL-23, and is in preliminary trials for psoriasis.

Apremilast: An oral inhibitor of type 4 phosphodiesterase (PDE4), apremilast inhibits production of inflammatory cytokines. Its mechanism of action on psoriasis is unclear. "Is it a floor wax or is it a milk shake? I can't decide. How does this drug work?" Dr. Leonardi asked.

Reports from a phase II trial by Celgene, which is developing the drug, suggest that it has multiple effects including reducing TNF-alpha, IL-2, interferon-gamma, and several leukotrienes, he said. In the trial of 260 patients, 24% of patients on a 20-mg b.i.d. dosage achieved a 75% improvement in their Psoriasis Area and Severity Index (PASI 75) score at 12 weeks, compared with 10% of patients on either a 20-mg/day dosage or placebo.

Tasocitinib: Also known as CP-690,550, this is a relatively selective inhibitor of JAK1 and JAK3. In early trials for rheumatoid arthritis, the oral drug appears to decrease inflammatory cytokines and chemokines, and decrease the influx of inflammatory cells, "so that provides a rationale for using it in psoriasis," Dr. Leonardi said.

In a phase II trial, 67% of patients on 15 mg b.i.d. achieved a PASI 75 score at 12 weeks, compared with 41% on 5 mg b.i.d., 25% on 2 mg b.i.d., and 2% on placebo. There were signals of potential safety issues with the drug, however, with a total of five major adverse events, some decreases in hemoglobin levels, transient decreases in polymorphonuclear leukocytes, and dose-related increases in lipids.

"Whether or not these are going to be significant, we'll have to wait and see," Dr. Leonardi said. "At least it showed some promise."

SDEF and this news organization are owned by Elsevier.

Dr. Leonardi declared having potential conflicts of interest with Pfizer (which is developing tasocitinib), Celgene (apremilast), Abbott (briakinumab and adalimumab), Centocor (ustekinumab, infliximab, and golimumab), Amgen (etanercept), Abgenix, Allergan, Alza, Biogen-IDEC, Boehringer-Ingelheim, Bristol-Myers Squibb, Connetics, Corixa, Fujisawa, Galderma, Genentech, Genzyme, GSK, Incyte, Isis, Lilly, MedImmune, Miravant, Schering Plough, Serono, Synta, Wyeth, and Xoma.

LAS VEGAS – There are so many psoriasis medications that have been approved or are in the experimental pipeline that it can be hard to track them all.

"I can't even keep them straight," Dr. Craig L. Leonardi said. "It's an amazing time right now."

He mapped out the major trends in psoriasis medications for physicians at a dermatology seminar sponsored by Skin Disease Education Foundation (SDEF).

The armamentarium started off with T-cell inhibitors, the main one being alefacept, said Dr. Leonardi of St. Louis University. "I'm not aware of any other T-cell inhibitors that are in development right now. This seems to be a strategy that has been pushed off to the side for now."

On the other hand, psoriasis drugs involving cytokines and cytokine inhibitors are booming. A few other anti-inflammatory strategies also are being tested, including activation of the sirtuin 1 (SIRT1) protein, an oral phospholipid analog, an oral phosphodiesterase inhibitor, and a drug that inhibits Janus kinase (JAK) 1 and 3.

Cytokines: "Cytokines and cytokine inhibitors are exploding," Dr. Leonardi said. The five approved tumor necrosis factor (TNF) antagonists – adalimumab, certolizumab, etanercept, infliximab, and golimumab – "have great utility," he said.

There are two drugs that block both interleukins (IL) 12 and 23. Ustekinumab is approved, and Abbott Laboratories in January 2011 withdrew its biologics license application for briakinumab to perform additional studies at the request of regulators. These two drugs seem to have a "class effect" associated with increased risk of major cardiovascular events, Dr. Leonardi said.

Two other experimental drugs inhibit just IL-23. "These drugs are not interacting with IL-12 at all. If the cardiovascular signal we have seen with briakinumab and with ustekinumab is real, maybe it has to do with IL-12 more than IL-23. Maybe we'll see an improved safety profile for targeting just IL-23," he said.

Trials are underway of three drugs that inhibit IL-17 and one that targets the IL-17 receptor.

"The IL-23 drugs, IL-17 drugs, and IL-17 receptor blocker drug have a lot of briakinumab/ustekinumab feel in terms of efficacy," Dr. Leonardi said. The studies are blinded, so he doesn't know which patients are getting drug or placebo, but he's noticed that in some patients "amazing things are happening to skin and they're happening fast. This is going to be a great moment for many psoriasis sufferers" if these drugs fulfill the promises he thinks he's glimpsed.

Another trial is studying an IL-22 blocking agent.

In other categories, the novel agents being studied are oral medications, "That's a good thing for those that like that approach, but when you use oral medication, you lose a lot of the specificity that we've come to really expect with our biologic agents," he said.

Resveratrol: This compound is believed to activate SIRT1, which may have anti-inflammatory properties. Preliminary trials are underway.

VB-201: The first drug in its class, VB-201 by Vascular Biogenics is an oral phospholipid analog that downregulates production of proinflammatory cytokines by mature dendritic cells. It inhibits the shared p40 subunit of IL-12 and IL-23, and is in preliminary trials for psoriasis.

Apremilast: An oral inhibitor of type 4 phosphodiesterase (PDE4), apremilast inhibits production of inflammatory cytokines. Its mechanism of action on psoriasis is unclear. "Is it a floor wax or is it a milk shake? I can't decide. How does this drug work?" Dr. Leonardi asked.

Reports from a phase II trial by Celgene, which is developing the drug, suggest that it has multiple effects including reducing TNF-alpha, IL-2, interferon-gamma, and several leukotrienes, he said. In the trial of 260 patients, 24% of patients on a 20-mg b.i.d. dosage achieved a 75% improvement in their Psoriasis Area and Severity Index (PASI 75) score at 12 weeks, compared with 10% of patients on either a 20-mg/day dosage or placebo.

Tasocitinib: Also known as CP-690,550, this is a relatively selective inhibitor of JAK1 and JAK3. In early trials for rheumatoid arthritis, the oral drug appears to decrease inflammatory cytokines and chemokines, and decrease the influx of inflammatory cells, "so that provides a rationale for using it in psoriasis," Dr. Leonardi said.

In a phase II trial, 67% of patients on 15 mg b.i.d. achieved a PASI 75 score at 12 weeks, compared with 41% on 5 mg b.i.d., 25% on 2 mg b.i.d., and 2% on placebo. There were signals of potential safety issues with the drug, however, with a total of five major adverse events, some decreases in hemoglobin levels, transient decreases in polymorphonuclear leukocytes, and dose-related increases in lipids.

"Whether or not these are going to be significant, we'll have to wait and see," Dr. Leonardi said. "At least it showed some promise."

SDEF and this news organization are owned by Elsevier.

Dr. Leonardi declared having potential conflicts of interest with Pfizer (which is developing tasocitinib), Celgene (apremilast), Abbott (briakinumab and adalimumab), Centocor (ustekinumab, infliximab, and golimumab), Amgen (etanercept), Abgenix, Allergan, Alza, Biogen-IDEC, Boehringer-Ingelheim, Bristol-Myers Squibb, Connetics, Corixa, Fujisawa, Galderma, Genentech, Genzyme, GSK, Incyte, Isis, Lilly, MedImmune, Miravant, Schering Plough, Serono, Synta, Wyeth, and Xoma.